Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06121843
Protocol IDs
CA088-1005 (primary)
NCI-2024-00171
Study Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Summary

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in
combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed
and/or refractory multiple myeloma (RRMM).

Eligibility

  1. History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
  2. Measurable multiple myeloma (MM)
  3. Eastern Cooperative Oncology Group performance status of 0-1

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)


1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523


Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.